Antibody-based fusion proteins to target death receptors in cancer

Cancer Letters

Volumn 332, Issue 2, 2013, Pages 175-183

  de Bruyn, Marco ^a   Bremer, Edwin ^a   Helfrich, Wijnand ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Apoptosis; FasL; Immune therapy; ScFv; Targeting; TRAIL

Indexed keywords

DEATH RECEPTOR; FAS ANTIGEN; FAS LIGAND; HYBRID PROTEIN; IMATINIB; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; RITUXIMAB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; SINGLE CHAIN FRAGMENT VARIABLE FAS LIGAND FUSION PROTEIN; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ADVANCED CANCER; ANTIGEN BINDING; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER COMBINATION CHEMOTHERAPY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; LARGE CELL LYMPHOMA; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; UPREGULATION;

EID: 84876081114     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2010.11.006     Document Type: Review

References (75)

1. Stasi R. Gemtuzumab ozogamicin: an anti-CD33 immunoconjugate for the treatment of acute myeloid leukaemia. Exp. Opin. Biol. Ther. 2008, 8:527-540.
2. ten Cate B., Bremer E., de Bruyn M., Bijma T., Samplonius D., Schwemmlein M., Huls G., Fey G., Helfrich W. A novel AML-selective TRAIL fusion protein that is superior to Gemtuzumab Ozogamicin in terms of in vitro selectivity, activity and stability. Leukemia 2009.
3. Wajant H., Gerspach J., Pfizenmaier K. Tumor therapeutics by design: targeting and activation of death receptors. Cytokine Growth Factor Rev. 2005, 16:55-76.
4. Locksley R.M., Killeen N., Lenardo M.J. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001, 104:487-501.
5. Schulte M., Reiss K., Lettau M., Maretzky T., Ludwig A., Hartmann D., de Strooper B., Janssen O., Saftig P. ADAM10 regulates FasL cell surface expression and modulates FasL-induced cytotoxicity and activation-induced cell death. Cell Death Differ. 2007, 14:1040-1049.
6. Suda T., Hashimoto H., Tanaka M., Ochi T., Nagata S. Membrane Fas ligand kills human peripheral blood T lymphocytes, and soluble Fas ligand blocks the killing. J. Exp. Med. 1997, 186:2045-2050.
7. Schneider P., Holler N., Bodmer J.L., Hahne M., Frei K., Fontana A., Tschopp J. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 1998, 187:1205-1213.
8. O' Reilly L.A., Tai L., Lee L., Kruse E.A., Grabow S., Fairlie W.D., Haynes N.M., Tarlinton D.M., Zhang J.G., Belz G.T., Smyth M.J., Bouillet P., Robb L., Strasser A. Membrane-bound Fas ligand only is essential for Fas-induced apoptosis. Nature 2009, 461:659-663.
9. Muhlenbeck F., Schneider P., Bodmer J.L., Schwenzer R., Hauser A., Schubert G., Scheurich P., Moosmayer D., Tschopp J., Wajant H. The tumor necrosis factor-related Apoptosis-inducing ligand receptors TRAIL-R1 and TRAIL-R2 Have Distinct cross-linking requirements for initiation of apoptosis and are non-redundant in JNK activation. J. Biol. Chem. 2000, 275:32208-32213.
10. Wajant H., Moosmayer D., Wuest T., Bartke T., Gerlach E., Schonherr U., Peters N., Scheurich P., Pfizenmaier K. Differential activation of TRAIL-R1 and -2 by soluble and membrane TRAIL allows selective surface antigen-directed activation of TRAIL-R2 by a soluble TRAIL derivative. Oncogene 2001, 20:4101-4106.
11. Kelley R.F., Totpal K., Lindstrom S.H., Mathieu M., Billeci K., DeForge L., Pai R., Hymowitz S.G., Ashkenazi A. Receptor-selective mutants of apoptosis-inducing ligand 2/tumor necrosis factor-related apoptosis-inducing ligand reveal a greater contribution of death receptor (DR) 5 than DR4 to apoptosis signaling. J. Biol. Chem. 2005, 280:2205-2212.
12. Berg D., Lehne M., Muller N., Siegmund D., Munkel S., Sebald W., Pfizenmaier K., Wajant H. Enforced covalent trimerization increases the activity of the TNF ligand family members TRAIL and CD95L. Cell Death Differ. 2007, 14:2021-2034.
13. Holler N., Tardivel A., Kovacsovics-Bankowski M., Hertig S., Gaide O., Martinon F., Tinel A., Deperthes D., Calderara S., Schulthess T., Engel J., Schneider P., Tschopp J. Two adjacent trimeric Fas ligands are required for Fas signaling and formation of a death-inducing signaling complex. Mol. Cell Biol. 2003, 23:1428-1440.
14. Greaney P., Nahimana A., Lagopoulos L., Etter A.L., Aubry D., Attinger A., Beltraminelli N., Huni B., Bassi I., Sordat B., Demotz S., Dupuis M., Duchosal M.A. A Fas agonist induces high levels of apoptosis in haematological malignancies. Leukemia Res. 2006, 30:415-426.
15. Peter M.E., Krammer P.H. The CD95(APO-1/Fas) DISC and beyond. Cell Death Differ. 2003, 10:26-35.
16. Boatright K.M., Renatus M., Scott F.L., Sperandio S., Shin H., Pedersen I.M., Ricci J.E., Edris W.A., Sutherlin D.P., Green D.R., Salvesen G.S. A unified model for apical caspase activation. Mol. Cell 2003, 11:529-541.
17. Breckenridge D.G., Xue D. Regulation of mitochondrial membrane permeabilization by BCL-2 family proteins and caspases. Curr. Opin. Cell Biol. 2004, 16:647-652.
18. Trauth B.C., Klas C., Peters A.M., Matzku S., Moller P., Falk W., Debatin K.M., Krammer P.H. Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989, 245:301-305.
19. Yonehara S., Ishii A., Yonehara M. A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor. J. Exp. Med. 1989, 169:1747-1756.
20. Pitti R.M., Marsters S.A., Lawrence D.A., Roy M., Kischkel F.C., Dowd P., Huang A., Donahue C.J., Sherwood S.W., Baldwin D.T., Godowski P.J., Wood W.I., Gurney A.L., Hillan K.J., Cohen R.L., Goddard A.D., Botstein D., Ashkenazi A. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer. Nature 1998, 396:699-703.
21. Connor J.P., Felder M. Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance. Gynecol. Oncol. 2008, 111:330-335.
22. Hayashi S., Miura Y., Nishiyama T., Mitani M., Tateishi K., Sakai Y., Hashiramoto A., Kurosaka M., Shiozawa S., Doita M. Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis. Arthritis Rheum. 2007, 56:1067-1075.
23. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev. Cancer 2002, 2:420-430.
24. Merino D., Lalaoui N., Morizot A., Schneider P., Solary E., Micheau O. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol. Cell Biol. 2006, 26:7046-7055.
25. Clancy L., Mruk K., Archer K., Woelfel M., Mongkolsapaya J., Screaton G., Lenardo M.J., Chan F.K. Preligand assembly domain-mediated ligand-independent association between TRAIL receptor 4 (TR4) and TR2 regulates TRAIL-induced apoptosis. Proc. Natl. Acad. Sci. USA 2005, 102:18099-18104.
26. Wagner K.W., Punnoose E.A., Januario T., Lawrence D.A., Pitti R.M., Lancaster K., Lee D., von Goetz M., Yee S.F., Totpal K., Huw L., Katta V., Cavet G., Hymowitz S.G., Amler L., Ashkenazi A. Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat. Med. 2007, 13:1070-1077.
27. Ogasawara J., Watanabe-Fukunaga R., Adachi M., Matsuzawa A., Kasugai T., Kitamura Y., Itoh N., Suda T., Nagata S. Lethal effect of the anti-Fas antibody in mice. Nature 1993, 364:806-809.
28. Rikhof B., van der Graaf W.T., Meijer C., Le P.T., Meersma G.J., de Jong S., Fletcher J.A., Suurmeijer A.J. Abundant Fas expression by gastrointestinal stromal tumours may serve as a therapeutic target for MegaFasL. Br. J. Cancer 2008, 99:1600-1606.
29. Etter A.L., Bassi I., Germain S., Delaloye J.F., Tschopp J., Sordat B., Dupuis M. The combination of chemotherapy and intraperitoneal MegaFas Ligand improves treatment of ovarian carcinoma. Gynecol. Oncol. 2007, 107:14-21.
30. Raclaw K.A., Heemers H.V., Kidd E.M., Dehm S.M., Tindall D.J. Induction of FLIP expression by androgens protects prostate cancer cells from TRAIL-mediated apoptosis. Prostate 2008, 68:1696-1706.
31. Jung S.N., Park I., Kim M.J., Kang I., Choe W., Kim S.S., Ha J. Down-regulation of AMP-activated protein kinase sensitizes DU145 carcinoma to Fas-induced apoptosis via c-FLIP degradation. Exp. Cell Res. 2009.
32. Symes J.C., Kurin M., Fleshner N.E., Medin J.A. Fas-mediated killing of primary prostate cancer cells is increased by mitoxantrone and docetaxel. Mol. Cancer Ther. 2008, 7:3018-3028.
33. Samel D., Muller D., Gerspach J., ssohou-Luty C., Sass G., Tiegs G., Pfizenmaier K., Wajant H. Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted activation. J. Biol. Chem. 2003, 278:32077-32082.
34. Bremer E., ten C.B., Samplonius D.F., de Leij L.F., Helfrich W. CD7-restricted activation of Fas-mediated apoptosis: a novel therapeutic approach for acute T-cell leukemia. Blood 2006, 107:2863-2870.
35. Cope A.P., Schulze-Koops H., Aringer M. The central role of T cells in rheumatoid arthritis. Clin. Exp. Rheumatol. 2007, 25:S4-S11.
36. Bremer E., ten C.B., Samplonius D.F., Mueller N., Wajant H., Stel A.J., Chamuleau M., van de Loosdrecht A.A., Stieglmaier J., Fey G.H., Helfrich W. Superior activity of fusion protein scFvRit:sFasL over cotreatment with rituximab and Fas agonists. Cancer Res. 2008, 68:597-604.
37. Byrd J.C., Kitada S., Flinn I.W., Aron J.L., Pearson M., Lucas D., Reed J.C. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002, 99:1038-1043.
38. Stel A.J., ten Cate B., Jacobs S., Kok J.W., Spierings D.C.J., Dondorff M., Helfrich W., Kluin-Nelemans H.C., de Leij L.F.M.H., Withoff S., Kroesen B.J. Fas receptor clustering and involvement of the death receptor pathway in rituximab-mediated apoptosis with concomitant sensitization of lymphoma B Cells to Fas-induced apoptosis. J. Immunol. 2007, 178:2287-2295.
39. Vega M.I., Huerta-Yepez S., Jazirehi A.R., Garban H., Bonavida B. Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene 2005, 24:8114-8127.
40. Ashkenazi A., Herbst R.S. To kill a tumor cell: the potential of proapoptotic receptor agonists. J. Clin. Invest. 2008, 118:1979-1990.
41. Ashkenazi A., Holland P., Eckhardt S.G. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor-related apoptosis-inducing ligand (rhApo2L/TRAIL). J. Clin. Oncol. 2008, 26:3621-3630.
42. Hotte S.J., Hirte H.W., Chen E.X., Siu L.L., Le L.H., Corey A., Iacobucci A., MacLean M., Lo L., Fox N.L., Oza A.M. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin. Cancer Res. 2008, 14:3450-3455.
43. Marini P. Drug evaluation: lexatumumab, an intravenous human agonistic mAb targeting TRAIL receptor 2. Curr. Opin. Mol. Ther. 2006, 8:539-546.
44. Ashkenazi A. Targeting the extrinsic apoptosis pathway in cancer. Cytokine Growth Factor Rev. 2008, 19:325-331.
45. Soria J., Smit E., Khayat D., Besse B., Yang X., Hsu C., Reese D., Wiezorek J., Blackhall F. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J. Clin. Oncol. 2010, 28:1527-1533.
46. Herbst R.S., Eckhardt S.G., Kurzrock R., Ebbinghaus S., O'Dwyer P.J., Gordon M.S., Novotny W., Goldwasser M.A., Tohnya T.M., Lum B.L., Ashkenazi A., Jubb A.M., Mendelson D.S. Phase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancer. J. Clin. Oncol. 2010, 28:2839-2846.
47. Lemke J., Noack A., Adam D., Tchikov V., Bertsch U., Roder C., Schutze S., Wajant H., Kalthoff H., Trauzold A. TRAIL signaling is mediated by DR4 in pancreatic tumor cells despite the expression of functional DR5. J. Mol. Med. 2010.
48. MacFarlane M., Kohlhaas S.L., Sutcliffe M.J., Dyer M.J.S., Cohen M. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res. 2005, 65:11265-11270.
49. Natoni A., MacFarlane M., Inoue S., Walewska R., Majid A., Knee D., Stover D.R., Dyer M.J., Cohen G.M. TRAIL signals to apoptosis in chronic lymphocytic leukaemia cells primarily through TRAIL-R1 whereas cross-linked agonistic TRAIL-R2 antibodies facilitate signalling via TRAIL-R2. Br. J. Haematol. 2007, 139:568-577.
50. Bremer E., de B.M., Samplonius D.F., Bijma T., ten C.B., de Leij L.F., Helfrich W. Targeted delivery of a designed sTRAIL mutant results in superior apoptotic activity towards EGFR-positive tumor cells. J. Mol. Med. 2008, 86:909-924.
51. Fulda S., Wick W., Weller M., Debatin K. Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med. 2002, 8:808-815.
52. Brooks A.D., Ramirez T., Toh U., Onksen J., Elliott P.J., Murphy W.J., Sayers T.J. The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis. Ann. N. Y. Acad. Sci. 2005, 1059:160-167.
53. Johnson T.R., Stone K., Nikrad M., Yeh T., Zong W.X., Thompson C.B., Nesterov A., Kraft A.S. The proteasome inhibitor PS-341 overcomes TRAIL resistance in Bax and caspase 9-negative or Bcl-xL overexpressing cells. Oncogene 2003, 22:4953-4963.
54. Zhu H., Guo W., Zhang L., Davis J.J., Wu S., Teraishi F., Cao X., Smythe W.R., Fang B. Enhancing TRAIL-induced apoptosis by Bcl-X(L) siRNA. Cancer Biol. Ther. 2005, 4:393-397.
55. Zhu H., Guo W., Zhang L., Wu S., Teraishi F., Davis J.J., Dong F., Fang B. Proteasome inhibitors-mediated TRAIL resensitization and Bik accumulation. Cancer Biol. Ther. 2005, 4:781-786.
56. Bremer E., Samplonius D.F., Peipp M., van G.L., Kroesen B.J., Fey G.H., Gramatzki M., de Leij L.F., Helfrich W. Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7. Cancer Res. 2005, 65:3380-3388.
57. Stieglmaier J., Bremer E., Kellner C., Liebig T.M., ten C.B., Peipp M., Schulze-Koops H., Pfeiffer M., Buhring H.J., Greil J., Oduncu F., Emmerich B., Fey G.H., Helfrich W. Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein. Cancer Immunol. Immunother. 2008, 57:233-246.
58. Bremer E., van Dam G.M., de Bruyn M., van Riezen M., Dijkstra M., Kamps G., Helfrich W., Haisma H. Potent systemic anticancer activity of adenovirally expressed EGFR-selective TRAIL fusion protein. Mol. Ther. 2008.
59. Bremer E., Kuijlen J., Samplonius D., Walczak H., de L.L., Helfrich W. Target cell-restricted and -enhanced apoptosis induction by a scFv:sTRAIL fusion protein with specificity for the pancarcinoma-associated antigen EGP2. Int. J. Cancer 2004, 109:281-290.
60. Bremer E., Samplonius D., Kroesen B.J., van G.L., de L.L., Helfrich W. Exceptionally potent anti-tumor bystander activity of an scFv:sTRAIL fusion protein with specificity for EGP2 toward target antigen-negative tumor cells. Neoplasia 2004, 6:636-645.
61. Bremer E., Samplonius D.F., van G.L., Dijkstra M.H., Kroesen B.J., de Leij L.F., Helfrich W. Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with specificity for human EGFR. J. Biol. Chem. 2005, 280:10025-10033.
62. Stagg J., Sharkey J., Pommey S., Young R., Takeda K., Yagita H., Johnstone R.W., Smyth M.J. Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response. Proc. Natl. Acad. Sci. USA 2008, 105:16254-16259.
63. Maetzel D., Denzel S., Mack B., Canis M., Went P., Benk M., Kieu C., Papior P., Baeuerle P., Munz M., Gires O. Nuclear signalling by tumour-associated antigen EpCAM. Nat. Cell Biol. 2009, 11:162-171.
64. Tazzari P.L., Tabellini G., Ricci F., Papa V., Bortul R., Chiarini F., Evangelisti C., Martinelli G., Bontadini A., Cocco L., McCubrey J.A., Martelli A.M. Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. Cancer Res. 2008, 68:9394-9403.
65. Sussman R.T., Ricci M.S., Hart L.S., Sun S.Y., El Deiry W.S. Chemotherapy-resistant side-population of colon cancer cells has a higher sensitivity to TRAIL than the non-SP, a higher expression of c-Myc and TRAIL-receptor DR4. Cancer Biol. Ther. 2007, 6:1490-1495.
66. Todaro M., Lombardo Y., Francipane M.G., Alea M.P., Cammareri P., Iovino F., Di Stefano A.B., Di Bernardo C., Agrusa A., Condorelli G., Walczak H., Stassi G. Apoptosis resistance in epithelial tumors is mediated by tumor-cell-derived interleukin-4. Cell Death Differ. 2008, 15:762-772.
67. Visvader J., Lindeman G. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat. Rev. Cancer 2008, 8:755-768.
68. Mahalingam D., Szegezdi E., Keane M., Jong S., Samali A. TRAIL receptor signalling and modulation: are we on the right TRAIL?. Cancer Treat. Rev. 2009, 35:280-288.
69. Hoogwater F.J., Nijkamp M.W., Smakman N., Steller E.J., Emmink B.L., Westendorp B.F., Raats D.A., Sprick M.R., Schaefer U., van Houdt W.J., de Bruijn M.T., Schackmann R.C., Derksen P.W., Medema J.P., Walczak H., Rinkes I.H., Kranenburg O. Oncogenic K-Ras turns death receptors into metastasis-promoting receptors in human and mouse colorectal cancer cells. Gastroenterology 2010.
70. Trauzold A., Siegmund D., Schniewind B., Sipos B., Egberts J., Zorenkov D., Emme D., Roder C., Kalthoff H., Wajant H. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene 2006, 25:7434-7439.
71. Trauzold A., Roder C., Sipos B., Karsten K., Arlt A., Jiang P., Martin-Subero J.I., Siegmund D., Muerkoster S., Pagerols-Raluy L., Siebert R., Wajant H., Kalthoff H. CD95 and TRAF2 promote invasiveness of pancreatic cancer cells. FASEB J. 2005, 19:620-622.
72. Ehrenschwender M., Siegmund D., Wicovsky A., Kracht M., Dittrich-Breiholz O., Spindler V., Waschke J., Kalthoff H., Trauzold A., Wajant H. Mutant PIK3CA licenses TRAIL and CD95L to induce non-apoptotic caspase-8-mediated ROCK activation. Cell Death Differ. 2010.
73. Gores G.J., Kaufmann S.H. Is TRAIL hepatotoxic?. Hepatology 2001, 34:3-6.
74. Koschny R., Ganten T.M., Sykora J., Haas T.L., Sprick M.R., Kolb A., Stremmel W., Walczak H. TRAIL/bortezomib cotreatment is potentially hepatotoxic but induces cancer-specific apoptosis within a therapeutic window. Hepatology 2007, 45:649-658.
75. Watermann I., Gerspach J., Lehne M., Seufert J., Schneider B., Pfizenmaier K., Wajant H. Activation of CD95L fusion protein prodrugs by tumor-associated proteases. Cell Death Differ. 2007, 14:765-774.